HAND Definition
When carefully assessed, human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) affect approximately half of persons living with HIV (Heaton et al. 2010). Three subcategories of HAND can be distinguished using a combination of neuropsychological testing, neurological and medical examination, and ancillary testing (Antinori et al. 2007): asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD). Regardless of the severity of the HAND diagnosis, neuropsychological impairment is often associated with negative daily functioning outcomes such as unemployment and poor medication adherence (e.g., Hinkin et al. 2002). It is important to note, however, that impairment in daily functioning is a key criterion that distinguishes MND and HAD from ANI. One significant challenge in assigning HAND diagnoses is differentiating HAND from other illnesses that can have neurocognitive effects (e.g., substance...
References
Ances BM, Ortega M, Vaida F, Heaps J, Paul R. Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr. 2012;59(5):469–77. doi:10.1097/QAI.0b013e318249db17.
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99. doi:10.1212/01.WNL.0000287431.88658.8b.
Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27(9):1387–95. doi:10.1097/QAD.0b013e32836010bd.
Chang L, Andres M, Sadino J, Jiang CS, Nakama H, Miller E, Ernst T. Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage. 2011;58(4):1017–27. doi:10.1016/j.neuroimage.2011.07.010.
Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73(5):342–8.
Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 1992;42(9):1736–9.
Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8(1):33–44. doi:10.1038/nrn2040.
Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25(14):1747–51. doi:10.1097/QAD.0b013e32834a40cd.
Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best BM, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014;58(7):1015–22.
Grant I, Franklin Jr DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055–62.
Grill-Spector K, Henson R, Martin A. Repetition and the brain: neural models of stimulus-specific effects. Trends Cogn Sci. 2006;10(1):14–23. doi:10.1016/j.tics.2005.11.006.
Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology. 2010;75(23):2087–96. doi:10.1212/WNL.0b013e318200d727.
Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944–50. http://www.ncbi.nlm.nih.gov/pubmed/12499488
Jiang X, Bollich A, Cox P, Hyder E, James J, Gowani SA, Hadjikhani N, Blanz V, Manoach DS, Barton JJ, Gaillard WD, Riesenhuber M. A quantitative link between face discrimination deficits and neuronal selectivity for faces in autism. Neuroimage: Clinical. 2013;2:320–331.
Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61(3):381–9. doi:10.1097/QAI.0b013e3182690e3c.
Letendre S, FitzSimons C, Ellis R, Group C. Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort. In: Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. 2010.
Letendre S, Ellis RJ, Best BB, Bhatt A, Marquie-Beck J, LeBlanc S, et al. Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2009;8:169–183.
Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56(3):416–23.
Liu C, Wang C, Leclair M, Young M, Jiang X. Reduced neural specificity in middle-aged HIV+ women in the absence of behavioral deficits. Neuroimage: Clinical. 2015. doi:10.1016/j.nicl.2014.12.003
Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, Morgello S, Gabuzda D. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr. 2011;57(5):371–9. doi:10.1097/QAI.0b013e3182237e54.
Mahy M, Autenrieth CS, Stanecki K, Wynd S. Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data. AIDS. 2014;28 Suppl 4:S453–9.
McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78(7):485–92. doi:10.1212/WNL.0b013e3182478d64.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9. doi:10.1016/j.jalz.2011.03.005.
Mind-Exchange-Working-Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56(7):1004–17.
Moore DJ, Letendre SL, Morris S, Umlauf A, Deutsch R, Smith DM, Little S, Rooney A, Franklin DR, Gouaux B, Leblanc S, Rosario D, Fennema-Notestine C, Heaton RK, Ellis RJ, Atkinson JH, Grant I. Neurocognitive functioning in acute or early HIV infection. J Neurovirol. 2011;17(1):50–7.
Overton ET, Kauwe JS, Paul R, Tashima K, Tate DF, Patel P, Carpenter CC, Patty D, Brooks JT, Clifford DB. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav. 2011;15(8):1902–9. doi:10.1007/s10461-011-0033-9.
Soontornniyomkij V, Umlauf A, Chung SA, Cochran ML, Soontornniyomkij B, Gouaux B, Toperoff W, et al. HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS. 2014;28(9):1297–306. doi:10.1097/QAD.0000000000000262.
Towgood KJ, Pitkanen M, Kulasegaram R, Fradera A, Kumar A, Soni S, Sibtain NA, et al. Mapping the brain in younger and older asymptomatic HIV-1 men: frontal volume changes in the absence of other cortical or diffusion tensor abnormalities. Cortex. 2011;48(2):230–41. doi:10.1016/j.cortex.2011.03.006.
Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D’Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS. 1999;13(14):1889–97.
Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011;53(8):836–42. doi:10.1093/cid/cir524.
Woods SP, Weber E, Weisz BM, Twamley EW, Grant I, HIV Neurobehavioral Research Programs Group. Prospective memory deficits are associated with unemployment in persons living with HIV infection. Rehabil Psychol. 2011;56(1):77–84. doi:10.1037/a0022753.
Young AC, Yiannoutsos CT, Hegde M, Lee E, Peterson J, Walter R, Price RW, Meyerhoff DJ, Spudich S. Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology. 2014;83(18):1592–600.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this entry
Cite this entry
Jiang, X., Moore, D.J., Ellis, R.J. (2015). HIV Neurocognitive Diagnosis, Natural History, and Treatment. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_219-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_219-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine